{
    "clinical_study": {
        "@rank": "52215", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical Tretinoin"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "One-third of all malignancies in the United States (approximately one million cases\n      diagnosed annually) are nonmelanoma skin cancer (NMSC). NMSC causes considerable morbidity,\n      economic burden, facial deformity and at least 1,000 deaths annually. Prevention of these\n      malignancies with a topical agent free of serious side effects would confer substantial\n      public health benefit. Three hundred fifty thousand veterans were expected to develop NMSC\n      in 1994. NMSC is one of the most common conditions requiring dermatologic care in the VA\n      system. Topical tretinoin has been used extensively to treat photoaged skin. Retinoids\n      administered orally in high doses appear to be effective in chemoprevention of nonmelanoma\n      skin cancer but have unacceptable toxicity. In this study, 1131 patients with a recent\n      history of squamous cell and/or basal cell carcinoma were enrolled at six participating\n      centers over a four-year period and were randomly assigned to either 0.1% tretinoin cream or\n      placebo. They were followed for a minimum of two years to determine if topical tretinoin is\n      effective in reducing the risk of new occurrences."
        }, 
        "brief_title": "Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer", 
        "completion_date": {
            "#text": "July 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "Carcinoma, Basal Cell", 
            "Carcinoma, Squamous Cell", 
            "Skin Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Skin Neoplasms", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Squamous Cell", 
                "Carcinoma, Basosquamous"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Hypothesis:   To determine the efficacy of topical tretinoin cream for the\n      prevention of nonmelanoma skin cancer (NMSC) among high risk individuals (at least 2 NMSC?S\n      in last 5 years).\n\n      Secondary Hypothesis:   Secondary objectives are: (a) to determine the long-term effect of\n      topical tretinoin on the prevalence of premalignant actinic  keratoses, and (b) to\n      distinguish subpopulations in which topical tretinoin is particularly effective or\n      ineffective,  compared to the overall study population.\n\n      Intervention:  Apply Tretinoin 0.1% cream or placebo cream to face and ears twice a day.\n\n      Primary Outcomes:   New NMSC lesions on the face and ears. Number of actinic keratoses on\n      the face and ears.\n\n      Study Abstract:  One-third of all malignancies in the United States (approximately one\n      million cases diagnosed annually) are nonmelanoma skin cancer (NMSC).  NMSC causes\n      considerable morbidity, economic burden, facial deformity and at least 1,000 deaths\n      annually.  Prevention of these malignancies with a topical agent free of serious side\n      effects would confer substantial public health benefit.  Three hundred fifty thousand\n      veterans were expected to develop NMSC in 1994.  NMSC is one of the most common conditions\n      requiring dermatologic care in the VA system.\n\n      Topical tretinoin has been used extensively to treat photoaged skin.  Retinoids administered\n      orally in high doses appear to be effective in chemoprevention of nonmelanoma skin cancer\n      but have unacceptable toxicity.  In this study, 1200 patients with a recent history of\n      squamous cell and/or basal cell carcinoma will be enrolled at six participating centers over\n      a four-year period and will be randomly assigned to either 0.1% tretinoin cream or placebo.\n      They will be followed for a minimum of two years to determine if topical tretinoin is\n      effective in reducing the risk of new occurrences.\n\n      Weinstock, M.A., Bingham, S.F., Cole, G.W., Eilers, D., Naylor, M.F., Kalivas, J., Taylor,\n      J.R., Gladstone, H.B., Piacquadio, D.J., and DiGiovanna, J.J.  Reliability of Counting\n      Actinic Keratoses Before and After Brief Consensus Discussion.  Arch Dermatol 137:1055-1058,\n      2001"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        High risk individuals (at least 2 NMSC?S in last 5 years).\n\n        Exclusion Criteria:\n\n        Exclusion criteria would include systemic retinoid treatment or systemic chemotherapy\n        within the past six months; indices of very high mortality risk within 3 years (history of\n        invasive noncutaneous malignancy within the past five years or metastatic cutaneous\n        malignancy, or of other severe medical problems e.g. end-stage cardiac disease); known\n        allergy or severe irritation reaction to tretinoin or the cream vehicle; special\n        conditions predisposing to NMSC that may not be generally applicable (xeroderma\n        pigmentosum, basal cell nevus syndrome, major organ transplant recipient, known arsenic\n        exposure, PUVA photochemotherapy, mycosis fungoides, or prior or current radiation therapy\n        involving the face, ears, or area of prior skin cancer), and likely inability to comply\n        with the requirements of the trial as judged by the investigator.  Incompetent patients\n        and pregnant or nursing patients will be excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "1131", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 29, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00007631", 
            "org_study_id": "402"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "intervention_name": "Tretinoin 0.1% cream or placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "Patients receive placebo for same amount of time", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tretinoin"
        }, 
        "keyword": [
            "NMSC", 
            "nonmelanoma skin cancer", 
            "topical tretinoin cream"
        ], 
        "lastchanged_date": "January 29, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85012"
                    }, 
                    "name": "Carl T. Hayden VA Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90822"
                    }, 
                    "name": "VA Medical Center, Long Beach"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33125"
                    }, 
                    "name": "VA Medical Center, Miami"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hines", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60141-5000"
                    }, 
                    "name": "Edward Hines, Jr. VA Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "VA Medical Center, Durham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "VA Medical Center, Oklahoma City"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02908"
                    }, 
                    "name": "VA Medical Center, Providence"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "CSP #402 - VA Topical Tretinoin Chemoprevention Trial", 
        "overall_official": {
            "affiliation": "VA Medical Center, Providence", 
            "last_name": "Martin A. Weinstock, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Long term effect of topical tretinoin on the prevalence of premalignant actinic keratoses", 
            "safety_issue": "No", 
            "time_frame": "until the end of the study for a minimum of 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00007631"
        }, 
        "responsible_party": {
            "name_title": "Weinstock, Martin - Study Chair", 
            "organization": "Department of Veterans Affairs"
        }, 
        "source": "Department of Veterans Affairs", 
        "sponsors": {
            "collaborator": {
                "agency": "Ortho Dermatologics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "March 1998", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2009"
    }, 
    "geocoordinates": {
        "Carl T. Hayden VA Medical Center": "33.448 -112.074", 
        "Edward Hines, Jr. VA Hospital": "41.854 -87.84", 
        "VA Medical Center, Durham": "35.994 -78.899", 
        "VA Medical Center, Long Beach": "33.804 -118.158", 
        "VA Medical Center, Miami": "25.789 -80.226", 
        "VA Medical Center, Oklahoma City": "35.468 -97.516", 
        "VA Medical Center, Providence": "41.824 -71.413"
    }
}